Melanotan 2 vs PT-141: Comparing Melanocortin Research Compounds (UK 2026)

Melanotan 2 (MT-II) and PT-141 (Bremelanotide) are both synthetic melanocortin peptides derived from alpha-melanocyte-stimulating hormone (α-MSH), and both activate melanocortin receptors. However, they differ in receptor selectivity, pharmacological profiles, regulatory status, and intended research applications. Understanding these differences is essential for researchers working in the melanocortin system.

Structural Relationship

Both compounds were developed from the naturally occurring α-MSH sequence at the University of Arizona. α-MSH is a tridecapeptide (13 amino acids) derived from ACTH that activates all five melanocortin receptor subtypes (MC1R–MC5R) with varying affinities.

Melanotan 2 is a cyclic lactam analogue of α-MSH — specifically [Nle4, D-Phe7]-α-MSH with a cyclic structure formed by a lactam bridge between Lys5 and Asp10. This cyclisation improves metabolic stability and receptor binding affinity versus linear α-MSH. MT-II is a non-selective agonist with significant activity at MC1R, MC3R, MC4R, and MC5R.

PT-141 was derived from Melanotan 2 — it is actually a metabolite of MT-II that forms in vivo after MT-II administration. Researchers isolated this metabolite and characterised it as retaining the sexual arousal properties of MT-II with reduced pigmentation activity (lower MC1R engagement). PT-141 is a heptapeptide fragment with modifications to the parent sequence.

Receptor Selectivity: The Key Difference

Melanotan 2 activates all MC subtypes with relatively non-selective agonism. Its most prominent effects are:

MC1R (melanocytes): Potent stimulation of eumelanin production — skin darkening. This is the “tanning” effect and was the original target of Melanotan development.

MC3R/MC4R (CNS): Sexual arousal and appetite suppression effects.

MC5R (exocrine glands): Effects on sebaceous and other exocrine gland secretions.

PT-141 has been developed to preferentially activate MC3R and MC4R while producing less MC1R stimulation. This selectivity profile preserves the central sexual arousal effects while substantially reducing the pigmentation effects — making it a more targeted research tool for studying melanocortin-mediated sexual function without confounding melanogenesis effects.

Pigmentation Effects

MT-II produces substantial skin darkening through MC1R-mediated melanogenesis in melanocytes. This is dose-dependent and persistent — lasting weeks after treatment ends. Freckles and existing moles may darken significantly. In research, this pigmentation effect is both a feature (useful for studying melanogenesis and skin pigmentation biology) and a confounder (when the research question concerns sexual function rather than pigmentation).

PT-141 produces substantially less pigmentation than MT-II due to reduced MC1R activity, allowing the sexual function research angle to be studied with less pigmentation confounding.

Sexual Function Research

Both compounds stimulate sexual arousal through CNS MC3R/MC4R activation — producing downstream dopamine release in the mesolimbic pathway and oxytocin release from hypothalamic neurons. MT-II has been shown in early human studies to produce erections in men (including those with organic erectile dysfunction) through this central mechanism.

PT-141/Bremelanotide was developed as the more targeted clinical candidate and has progressed to FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women (as Vyleesi, 2019). For researchers specifically studying melanocortin-mediated sexual function without pigmentation confounding, PT-141 is the more appropriate tool.

For researchers studying the relationship between melanogenesis and sexual arousal — or examining all MC receptor subtypes simultaneously — MT-II’s broader receptor profile is a feature rather than a limitation.

Appetite Suppression Research

MC4R activation in the hypothalamus suppresses food intake — MC4R knockout mice develop severe obesity, and MC4R agonism is one of the most effective pharmacological approaches to appetite suppression in rodent models. Both MT-II and PT-141 produce appetite suppression through this mechanism, though the effect may be more pronounced with MT-II given its less selective MC4R engagement alongside MC3R.

For obesity and appetite regulation research, both compounds are relevant. Researchers should consider whether the pigmentation confound of MT-II is acceptable in their study design.

Safety Considerations for Research

Both compounds can produce nausea (a common side effect of melanocortin receptor activation, related to area postrema stimulation) and transient blood pressure changes. MT-II has been associated with more prominent nausea and with spontaneous erections (in male subjects) at doses used for tanning purposes.

PT-141’s clinical pharmacology data from Phase III trials provides a well-characterised safety reference profile: nausea is the most common side effect (approximately 40% of subjects), with transient blood pressure elevation (mean +6 mmHg systolic at peak) observed and generally mild.

Regulatory Status

PT-141/Bremelanotide is FDA-approved in the US (as Vyleesi) for premenopausal HSDD — giving it regulatory validation as a clinical compound. In the UK, it is not licensed and is supplied as a research compound under RUO designation.

Melanotan 2 has no regulatory approval in any jurisdiction and has been the subject of MHRA warnings in the UK due to some suppliers making medicinal claims. It is available as a research compound under RUO designation from legitimate suppliers.

Summary: Which for Which Research Question?

For pigmentation and melanogenesis research: MT-II is the more appropriate tool, with its strong MC1R activity driving the melanogenic cascade directly.

For sexual function research with minimal pigmentation confound: PT-141 is the more selective choice, with clinical trial data supporting its mechanism and dosing.

For appetite regulation and obesity research: Both compounds are relevant; MT-II’s broader profile may produce larger appetite effects.

For comprehensive MC receptor system research across all five receptor subtypes: MT-II’s non-selective profile makes it the broader research tool.